Form 4: Astera Labs CEO Sells Shares Under 10b5-1 Plan

Astera Labs CEO Jitendra Mohan has sold a significant number of company shares through a pre-arranged trading plan, as disclosed in a Form 4 filing.

Summary

• Jitendra Mohan, CEO of Astera Labs, Inc. (ALAB), reported the sale of company common stock on April 10, 2026.
• The sales were executed automatically under a Rule 10b5-1 trading plan adopted on December 1, 2025.
• A total of 123,750 shares were sold across multiple transactions.
• The weighted average sale price for a portion of the shares was $149.53, with individual sales ranging from $149.00 to $149.99.
• Another portion of shares was sold at a weighted average price of $150.25, with individual sales ranging from $150.00 to $150.63.
• Following these transactions, Mohan's direct beneficial ownership of common stock is 1,452,739 shares.
• Additional shares are held indirectly through various trusts, including a Living Trust, an estate planning trust, and two 2021 and two 2022 trusts.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event due to the significant volume of shares sold by the CEO, despite being executed under a pre-arranged plan.

Negatives

• The CEO sold a substantial number of shares, which could be perceived negatively by the market.
• The total value of the shares sold is significant, although the exact total is not explicitly stated, it is implied by the number of shares and the price range.

Risks

• The sale of shares by a CEO, even under a 10b5-1 plan, can sometimes be interpreted as a lack of confidence in the company's future prospects by investors.
• While the plan was established in December 2025, the execution in April 2026 coincides with the reporting date, and market perception could be influenced by recent stock performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The Reporting Person disclaims beneficial ownership of securities held by trusts, except to the extent of his pecuniary interest therein, and the filing is not an admission of beneficial ownership for purposes of Section 16 or any other purpose.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event for executives of growth companies like Astera Labs, especially after periods of significant stock appreciation. Such plans are designed to allow executives to diversify their holdings and manage personal finances without being accused of insider trading, but they can still influence market sentiment.

Stakeholder Impact

• Shareholders: May perceive the CEO's sale as a negative signal, potentially impacting short-term stock price, although the 10b5-1 plan mitigates insider trading concerns.
• Employees: May also interpret the sale negatively, potentially affecting morale.
• Management: The CEO is diversifying personal assets, a common practice for executives.

Key Dates

Recommendation

The filing reports routine insider selling under a pre-established 10b5-1 plan, which is a standard practice for executives to diversify holdings. While the volume of shares sold is notable, it does not inherently signal a fundamental change in the company's prospects or valuation. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor future performance and strategic developments rather than reacting solely to this transaction.

Keywords

Astera Labs, ALAB, Form 4, Insider Trading, Stock Sale, CEO, Jitendra Mohan, Rule 10b5-1, Beneficial Ownership, Securities Exchange Act